Effectiveness and Safety of Apixaban versus Rivaroxaban in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus.

Krishna Roy ChowdhuryJonathan MichaudOriana Hoi Yun YuHui YinLaurent Azoulay Christel Renoux

Published in: Thrombosis and haemostasis (2022)

Among patients with NVAF and T2DM, apixaban was associated with a similar risk of stroke and a lower risk of major bleeding compared with rivaroxaban.

Keyphrases

atrial fibrillation
glycemic control
venous thromboembolism
type diabetes
cardiovascular disease
weight loss
blood brain barrier